Pitfalls and prevention strategies for liquid chromatography-tandem mass spectrometry in the selected reaction-monitoring mode for drug analysis

Clinical Chemistry

Volumn 54, Issue 9, 2008, Pages 1519-1527

  Sauvage, François Ludovic ^a,c   Gaulier, Jean Michel ^a   Lachâtre, Gérard ^a,b   Marquet, Pierre ^a,c  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF LIMOGES   (France)

^c Univ Limoges   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE; ANTIDEPRESSANT AGENT; ATROPINE; BENZOYLECGONINE; CLOMIPRAMINE; LYSERGIDE; PHENOTHIAZINE; ZOLPIDEM;

ARTICLE; DRUG ANALYSIS; DRUG MONITORING; DRUG SCREENING; FALSE POSITIVE RESULT; LIQUID CHROMATOGRAPHY; SENSITIVITY AND SPECIFICITY; STANDARD; TANDEM MASS SPECTROMETRY;

ATROPINE; CHROMATOGRAPHY, LIQUID; CLOMIPRAMINE; HUMANS; LYSERGIC ACID DIETHYLAMIDE; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; PHENOTHIAZINES; TANDEM MASS SPECTROMETRY;

EID: 51349162644     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2008.105478     Document Type: Article

References (38)

1. Ackermann BL, Berna MJ, Murphy AT. Recent advances in use of LC/MS/MS for quantitative high-throughput bioanalytical support of drug discovery. Curr Top Med Chem 2002;2:53-66.
2. Hopfgartner G, Husser C, Zell M. High-throughput quantification of drugs and their metabolites in biosamples by LC-MS/MS and CE-MS/MS: possibilities and limitations. Ther Drug Monit 2002;24:134-43.
3. Niessen WM. Progress in liquid chromatography-mass spectrometry instrumentation and its impact on high-throughput screening. J Chromatogr A 2003;1000:413-36.
4. Bogusz MJ. Liquid chromatography-mass spectrometry as a routine method in forensic sciences: a proof of maturity. J Chromatogr B Analyt Technol Biomed Life Sci 2000;748:3-19.
5. Hoja H, Marquet P, Verneuil B, Lotfi H, Penicaut B, Lachâtre G. Applications of liquid chromatography-mass spectrometry in analytical toxicology: a review. J Anal Toxicol 1997;21:116-26.
6. Maurer HH. Multi-analyte procedures for screening for and quantification of drugs in blood, plasma, or serum by liquid chromatography-single stage or tandem mass spectrometry (LC-MS or LC-MS/MS) relevant to clinical and forensic toxicology. Clin Biochem 2005;38:310-8.
7. Marquet P, Lachâtre G. Liquid chromatography-mass spectrometry: potential in forensic and clinical toxicology. J Chromatogr B Analyt Technol Biomed Life Sci 1999;733:93-118.
8. Van Bocxlaer JF, Clauwaert KM, Lambert WE, Deforce DL, Van den Eeckhout EG, De Leenheer AP. Liquid chromatography-mass spectrometry in forensic toxicology. Mass Spectrom Rev 2000;19:165-214.
9. Marquet P. Progress of liquid chromatography-mass spectrometry in clinical and forensic toxicology. Ther Drug Monit 2002;24:255-76.
10. Saint-Marcoux F, Sauvage FL, Marquet P. Current role of LC-MS in therapeutic drug monitoring. Anal Bioanal Chem 2007;388:1327-49.
11. Maurer HH. Current role of liquid chromatography-mass spectrometry in clinical and forensic toxicology. Anal Bioanal Chem 2007;388:1315-25.
12. Peters FT, Drummer OH, Musshoff F. Validation of new methods. Forensic Sci Int 2007;165:216-24.
13. Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, et al. Bioanalytical method validation: a revisit with a decade of progress. Pharm Res 2000;17:1551-7.
14. De Zeeuw RA. Substance identification: the weak link in analytical toxicology. J Chromatogr B Analyt Technol Biomed Life Sci 2004;811:3-12.
15. Rivier L. Criteria for the identification of compounds by liquid chromatography-mass spectrometry and liquid chromatography-multiple mass spectrometry in forensic toxicology and doping analysis. Anal Chim Acta 2003;492:69-82.
16. Milman BL. Identification of chemical compounds. Trends Analyt Chem 2005;24:493-508.
17. Maralikova B, Weinmann W. Confirmatory analysis for drugs of abuse in plasma and urine by high-performance liquid chromatography-tandem mass spectrometry with respect to criteria for compound identification. J Chromatogr B Analyt Technol Biomed Life Sci 2004;811:21-30.
18. Laboratory accreditation requirements and operating standards. Version 1.0. Montreal: World Anti-Doping Agency; 2002.
19. Forensic toxicology laboratory guidelines. Washington (DC): Society of Forensic Toxicology/American Academy of Forensic Science; 2002.
20. Aderjan R, Briellmann T, Daldrup T, Demme U, Harzer K, Herbold M, et al. Richtlinien der GTFCh zur Qualitätssicherung bei forensisch-toxikologischen Untersuchungen. Toxichem Krimtech 1998;65:18-25.
21. European Union Decision 2002/657/EC 17.08.2002: commission decision laying down performance criteria for the analytical methods to be used for certain substances and residues thereof in live animals and animal products. Off J Eur Commun 2002;221:8-32.
22. US Department of Health and Human Services - Food and Drug Administration. (2003) Guidance for industry: mass spectrometry for confirmation of the identity of animal drug residues: final guidance. FDA, Washington, DC; 2003. Available from: http://www.fda.gov/cvm/Guidance/guide118.pdf.
23. International Standard for Laboratories. Version 2. Montreal: World Anti-Doping Agency; February 20, 2003.
24. Allen KR. Interference by venlafaxine ingestion in the detection of tramadol by liquid chromatography linked to tandem mass spectrometry for the screening of illicit drugs in human urine. Clin Toxicol (Phila) 2006;44:147-53.
25. Nordgren HK, Holmgren P, Liljeberg P, Eriksson N, Beck O. Application of direct urine LC-MS-MS analysis for screening of novel substances in drug abusers. J Anal Toxicol 2005;29:234-9.
26. Sauvage FL, Saint-Marcoux F, Duretz B, Deporte D, Lachâtre G, Marquet P. Screening of drugs and toxic compounds with liquid chromatography-linear ion trap tandem mass spectrometry. Clin Chem 2006;52:1735-42.
27. Hoja H, Marquet P, Verneuil B, Lotfi H, Dupuy JL, Lachâtre G. Determination of LSD and N-demethyl-LSD in urine by liquid chromatography coupled to electrospray ionization mass spectrometry. J Chromatogr B Biomed Sci Appl 1997;692:329-35.
28. Clarkson ED, Lesser D, Paul BD. Effective GC-MS procedure for detecting iso-LSD in urine after base-catalyzed conversion to LSD. Clin Chem 1998;44:287-92.
29. Von Moltke LL, Greenblatt DJ, Granda BW, Duan SX, Grassi JM, Venkatakrishnan K, et al. Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. Br J Clin Pharmacol 1999;48:89-97.
30. Pichard L, Gillet G, Bonfils C, Domergue J, Thenot JP, Maurel P. Oxidative metabolism of zolpidem by human liver cytochrome P450S. Drug Metab Dispos 1995;23:1253-62.
31. Quintela O, Sauvage FL, Charvier F, Gaulier JM, Lachâtre G, Marquet P. Highly sensitive liquid chromatography-tandem mass spectrometry determination of 21 benzodiazepines, metabolites and analogues in urine for the investigation of drug facilitated sexual assault cases. Clin Chem 2006;52:1346-55.
32. Joyce C, Smyth WF, Ramachandran VN, O'Kane E, Coulter DJ. The characterisation of selected drugs with amine-containing side chains using electrospray ionisation and ion trap mass spectrometry and their determination by HPLC-ESI-MS. J Pharm Biomed Anal 2004;36:465-76.
33. Boermans PA, Go HS, Wessels AM, Uges DR. Quantification by HPLC-MS/MS of atropine in human serum and clinical presentation of six mild-to-moderate intoxicated atropine-adulterated-cocaine users. Ther Drug Monit 2006;28:295-8.
34. Kirchherr H, Kühn-Velten WN. Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach. J Chromatogr B Analyt Technol Biomed Life Sci 2006;843:100-13.
35. Gergov M, Ojanpera I, Vuori E. Simultaneous screening for 238 drugs in blood by liquid chromatography-ion spray tandem mass spectrometry with multiple-reaction monitoring. J Chromatogr B Analyt Technol Biomed Life Sci 2003;795:41-53.
36. Rezai T, Kozak M. A semi-quantitative general unknown screening method for drugs and toxic compounds in urine using liquid chromatography-mass spectrometry. Ther Drug Monit 2007;29:492.
37. Mueller CA, Weinmann W, Dresen S, Schreiber A, Gergov M. Development of a multi-target screening analysis for 301 drugs using a QTrap liquid chromatography/tandem mass spectrometry system and automated library searching. Rapid Commun Mass Spectrom 2005;19:1332-8.
38. Sauvage FL, Gaulier JM, Lachâtre G, Marquet P. A fully automated turbulent-flow liquid chromatography-tandem mass spectrometry technique for monitoring antidepressants in human serum. Ther Drug Monit 2006;28:123-30.